Tecan Group Ltd. Stock

CHF167.00

0.54% today

SIX Swiss Exchange, Jul 29, 02:45 pm CET

ISIN

CH0012100191

Symbol

TECN

Index

SMIM, STOXX Europe 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Overview Dividends Analysts Charts Strategies

Tecan Group Ltd. Stock price

CHF166.10

-219.90 56.97% 5Y

SIX Swiss Exchange, Closing price Mon, Jul 28 2025

+0.40 0.24%

ISIN

CH0012100191

Symbol

TECN

Index

SMIM, STOXX Europe 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Key metrics

Basic

Market capitalization

CHF2.1b

Enterprise Value

CHF2.0b

Net debt

positive

Cash

CHF406.0m

Shares outstanding

12.7m

Valuation (TTM | estimate)

P/E

31.3 | 24.3

P/S

2.3 | 2.3

EV/Sales

2.2 | 2.2

EV/FCF

17.3

P/B

1.5

Dividends

DPS

CHF3.00

Yield 1Y | 5Y

1.8% | 0.8%

Growth 1Y | 5Y

0.0% | 6.4%

Payout 1Y | 3Y

56.7% | 35.5%

Increased

0 Years

Financials (TTM | estimate)

Revenue

CHF934.3m | CHF932.0m

EBITDA

CHF148.0m | CHF168.6m

EBIT

CHF75.6m | CHF97.5m

Net Income

CHF67.7m | CHF87.0m

Free Cash Flow

CHF117.9m

Growth (TTM | estimate)

Revenue

-13.0% | -0.3%

EBITDA

-28.6% | 54.7%

EBIT

-44.4% | 38.7%

Net Income

-48.8% | 28.5%

Free Cash Flow

-6.2%

Financial Health

Equity Ratio

Return on Equity

ROCE

4.8%

ROIC

4.3%

Debt/Equity

0.2

EPS

CHF5.3

FCF per Share

CHF9.3

Short interest

Employees

Rev per Employee

CHF290.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Tecan Group Ltd. Stock Analysis

Unlock Scores for Free

??

15 Analysts have issued a Tecan Group Ltd. forecast:

8x Buy

53%

6x Hold

40%

More details on Analyst Estimates Including Price Targets

15 Analysts have issued a Tecan Group Ltd. forecast:

Buy

53%

Hold

40%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Tecan Group Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	934 934	13% 13% 100%
- Direct Costs	614 614	10% 10% 66%
Gross Profit	321 321	18% 18% 34%
- Selling and Administrative Expenses	183 183	4% 4% 20%
- Research and Development Expense	68 68	2% 2% 7%
EBITDA	148 148	29% 29% 16%
- Depreciation and Amortization	72 72	2% 2% 8%
EBIT (Operating Income) EBIT	76 76	44% 44% 8%
Net Profit	68 68	49% 49% 7%

In millions CHF.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Company Profile

Tecan Group AG operates as a holding company. The firm engages in the development, production and distribution of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. It operates through the following segments: Life Sciences Business and Partnering Business. The Life Sciences Business segment supplies end users with automated workflow solutions, which includes laboratory instruments, software packages, application know-how, services, consumables and spare parts. The Partnering Business segment develops and manufactures original equipment manufacturer instruments and components. The company was founded by Heinz Abplanalp, Heini Maurer, Heini Moeckli and Gallus Blatter on March 18, 1980 and is headquartered in Mannedorf, Switzerland.

Head office	Switzerland
CEO	Achim Leoprechting
Employees	3,208
Founded	1980
Website	www.tecan.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now